The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure

Metabolic Syndrome and Related Disorders - United States
doi 10.1089/met.2015.0038
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Mary Ann Liebert Inc

Related search

SGLT-2 Inhibitors and Their Potential in the Treatment of Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2013English

Heart Failure and Type 2 Diabetes: From CVOTs, With Hope

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Heart Failure: A Preventable and Treatable Complication of Type 2 Diabetes

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

Effects of Sodium Glucose Cotransporter Type 2 Inhibitors on Heart Failure

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

TNF Receptor 1/2 Predict Heart Failure Risk in Type 2 Diabetes Mellitus Patients

International Heart Journal
MedicineCardiovascular MedicineCardiology
2017English

The Adverse Impact of Type 2 Diabetes on Brain Volume in Heart Failure

Journal of Clinical and Experimental Neuropsychology
Clinical PsychologyNeurology
2013English

Ertugliflozin: A Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor for Glycemic Control in Type 2 Diabetes

Therapeutics and Clinical Risk Management
2018English

Use of DPP-4 Inhibitors in Type 2 Diabetes: Focus on Sitagliptin

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2010English

SGLT-2 Inhibitors – Are They to Stay?

Diabesity
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy